Company Quick10K Filing
PDL Biopharma
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 124 $366
10-Q 2019-11-06 Quarter: 2019-09-30
10-Q 2019-08-07 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-03-15 Annual: 2018-12-31
10-Q 2018-11-07 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-30
10-Q 2018-05-09 Quarter: 2018-03-31
10-K 2018-03-16 Annual: 2017-12-31
10-Q 2017-11-13 Quarter: 2017-09-30
10-Q 2017-08-03 Quarter: 2017-06-30
10-Q 2017-05-03 Quarter: 2017-03-31
10-K 2017-03-01 Annual: 2016-12-31
10-Q 2016-11-03 Quarter: 2016-09-30
10-Q 2016-08-04 Quarter: 2016-06-30
10-Q 2016-05-04 Quarter: 2016-03-31
10-K 2016-02-23 Annual: 2015-12-31
10-Q 2015-11-04 Quarter: 2015-09-30
10-Q 2015-08-05 Quarter: 2015-06-30
10-Q 2015-05-06 Quarter: 2015-03-31
10-K 2015-02-23 Annual: 2014-12-31
10-Q 2014-11-10 Quarter: 2014-09-30
10-Q 2014-08-18 Quarter: 2014-06-30
10-Q 2014-05-12 Quarter: 2014-03-31
10-K 2014-03-03 Annual: 2013-12-31
10-Q 2013-11-06 Quarter: 2013-09-30
10-Q 2013-08-08 Quarter: 2013-06-30
10-Q 2013-05-09 Quarter: 2013-03-31
10-K 2013-03-01 Annual: 2012-12-31
10-Q 2012-11-05 Quarter: 2012-09-30
10-Q 2012-08-02 Quarter: 2012-06-30
10-Q 2012-05-03 Quarter: 2012-03-31
10-K 2012-02-23 Annual: 2011-12-31
10-Q 2011-11-09 Quarter: 2011-09-30
10-Q 2011-07-29 Quarter: 2011-06-30
10-Q 2011-04-28 Quarter: 2011-03-31
10-K 2011-03-01 Annual: 2010-12-31
10-Q 2010-11-09 Quarter: 2010-09-30
10-Q 2010-07-29 Quarter: 2010-06-30
10-Q 2010-04-30 Quarter: 2010-03-31
10-K 2010-03-01 Annual: 2009-12-31
8-K 2020-01-15 Regulation FD, Exhibits
8-K 2019-12-19 Officers, Exhibits
8-K 2019-12-16 Other Events, Exhibits
8-K 2019-12-13 Sale of Shares, Regulation FD, Exhibits
8-K 2019-12-09 Other Events, Exhibits
8-K 2019-11-18 Officers
8-K 2019-11-14 Other Events, Exhibits
8-K 2019-11-06 Earnings, Regulation FD, Exhibits
8-K 2019-10-21
8-K 2019-10-03 Regulation FD, Exhibits
8-K 2019-09-17 Enter Agreement, Off-BS Arrangement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-09-13 Enter Agreement, Off-BS Arrangement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-09-11 Other Events, Exhibits
8-K 2019-08-29 Officers
8-K 2019-08-19 Officers, Exhibits
8-K 2019-08-07 Earnings, Regulation FD, Exhibits
8-K 2019-06-25 Officers
8-K 2019-06-24 Officers, Shareholder Vote, Other Events, Exhibits
8-K 2019-06-10 Other Events, Exhibits
8-K 2019-05-21 Regulation FD, Exhibits
8-K 2019-05-09 Earnings, Regulation FD, Exhibits
8-K 2019-04-16 Other Events, Exhibits
8-K 2019-04-11 Enter Agreement, Other Events, Exhibits
8-K 2019-04-10 Officers, Exhibits
8-K 2019-04-08 Regulation FD, Exhibits
8-K 2019-03-18 Regulation FD, Exhibits
8-K 2019-03-14 Earnings, Regulation FD, Exhibits
8-K 2019-03-12 Regulation FD, Exhibits
8-K 2019-03-04 Regulation FD, Exhibits
8-K 2019-01-07 Regulation FD, Exhibits
8-K 2018-12-21 Officers
8-K 2018-11-29 Officers
8-K 2018-11-27 Regulation FD, Exhibits
8-K 2018-11-06 Earnings, Officers, Regulation FD, Exhibits
8-K 2018-10-09 Other Events, Exhibits
8-K 2018-10-04 Officers
8-K 2018-10-02 Regulation FD, Exhibits
8-K 2018-09-24 Other Events, Exhibits
8-K 2018-09-05 Regulation FD, Exhibits
8-K 2018-08-08 Earnings, Regulation FD, Exhibits
8-K 2018-08-02 Enter Agreement, Regulation FD, Exhibits
8-K 2018-06-22 Officers, Other Events, Exhibits
8-K 2018-06-14 Officers, Exhibits
8-K 2018-06-12 Other Events
8-K 2018-06-11 Shareholder Vote, Other Events, Exhibits
8-K 2018-06-08 Regulation FD, Exhibits
8-K 2018-06-05 Regulation FD, Exhibits
8-K 2018-05-22 Regulation FD, Exhibits
8-K 2018-05-21 Other Events, Exhibits
8-K 2018-05-09 Earnings, Regulation FD, Exhibits
8-K 2018-04-16 Other Events, Exhibits
8-K 2018-04-09 Regulation FD, Exhibits
8-K 2018-04-09 Officers
8-K 2018-03-13 Regulation FD, Exhibits
8-K 2018-03-08 Earnings, Regulation FD, Exhibits
8-K 2018-02-21 Regulation FD, Exhibits
8-K 2018-02-20 Regulation FD, Exhibits

PDL Biopharma Financials

PDLI Metrics, Comps, Filings

Annual | Quarterly

Business

In this report all references to "PDL," "we," "us," "our" or the "Company" mean collectively PDL BioPharma, Inc. and its subsidiaries, except where it is made clear that the term means only PDL BioPharma, Inc.

We seek to provide a significant return for our stockholders by acquiring commercial stage pharmaceutical assets with multiple year revenue growth potential as well as late clinical stage pharmaceutical products. Our leadership team has extensive experience in acquiring, commercializing and managing the life cycle of therapeutic products domestically and internationally across a number of indications and modalities. We intend to leverage this experience by pursuing the acquisition, growth and potential monetization of pharmaceutical products and companies.

Historically, we generated a substantial portion of our revenues through the license agreements related to patents covering the humanization of antibodies, which we refer to as the Queen et al. patents. In 2012, we began providing alternative sources of capital through royalty monetizations and debt facilities, and, in 2016, we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, we have consummated seventeen such transactions, the following ten of which are active and outstanding:


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Scholar Rock Holding (SRRK) 439 0% -6.8 -25% 197 68 8 0 -49 -48 325
Replimune (REPL) 437 -13.2 -21% 144 13 0 0 -30 -30 397
Kodiak Sciences (KOD) 427 -12.6 -43% 78 8 0 0 -34 -29 359
Osiris Therapeutics (OSIR) 402 73% 31.1 36% 102 23 143 105 37 12 386
BioCryst Pharmaceuticals (BCRX) 401 88% -3.6 -108% 116 126 12 10 -126 -114 415
Agenus (AGEN) 397 0% -2.6 -57% 207 364 115 0 -117 -111 290
PDL Biopharma (PDLI) 366 62% 1.2 5% 890 225 129 81 44 68 81
Gritstone Oncology (GRTS) 356 0% -3.5 -33% 228 46 4 0 -75 -71 247
Acorda Therapeutics (ACOR) 351 79% 34.9 -7% 1,197 653 306 241 -79 6 203
AVROBIO (AVRO) 346 -4.3 -60% 102 9 0 0 -61 -60 256
LogicBio Therapeutics (LOGC) 294 -9.2 -43% 68 5 0 0 -29 -29 269
CASI (CASI) 290 -5.4 -35% 117 8 0 0 -41 -41 220
CEL-SCI (CVM) 267 -8.2 -112% 28 27 0 0 -32 -31 258
Eiger Biopharmaceuticals (EIGR) 267 -3.7 -51% 133 45 0 0 -68 -65 238
Gamida Cell (GMDA) 245 0% 65 0 0 0 0 241
Sutro Biopharma (STRO) 243 0% -6.5 -21% 189 69 46 0 -40 -35 231
La Jolla Pharmaceutical (LJPC) 227 86% -0.7 -93% 170 182 18 15 -158 -158 103
ADMA Biologics (ADMA) 222 -120% -4.7 -40% 143 96 18 -22 -57 -47 221
Cellular Biomedicine (CBMG) 191 54% -3.5 -36% 118 36 0 0 -43 -39 134
Solid Biosciences (SLDB) 179 -1.1 -101% 96 20 0 0 -97 -97 111

Balance Sheet ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash21216913194291219147527395
Accounts Receivable010000403122
Inventory3919
PP&E000900077
Assets3172692805449621,0161,2151,243964
Accounts Payable31100072013
Long-Term Debt429335410477246276150150
Liabilities641474348430502320460397234
Stockholders' Equity-324-204-68113460696751846730
Income Statement ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue3453623754435815903284198
Cost of Revenue643148
Gross Profit4372854150
R&D473
SG&A411825303536406363
Tax58108115137189168504313
Net Income9219921226532233364111-69
Cash Flow ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating18417021027129230110241-13
Cash Investing-37-24-69-298-138-80-14545957
Cash Financing-239-189-178-1043-294-29-119-176